| Welcome to the ALLHAT web site |
|
| ALLHAT
was the largest antihypertensive trial and the second largest lipid-lowering
trial and included large numbers of patients over age 65, women,
African-Americans, and patients with diabetes, treated largely in community
practice settings.
|
| A
total of 42,418 patients were enrolled between February 23, 1994 and January
31, 1998. A vanguard phase was conducted in the first half of 1994; the
full-scale trial began in the fall of 1994 and continued for eight years, until
March 31, 2002. The last participant visit was March 31, 2002. The results of
the trial were released December 17, 2002.
|
| ALLHAT
continues to analyze data for presentations and publications on secondary
outcomes, outcomes in subgroups, and other topics for both the antihypertensive
component and the lipid-lowering component of the trial. There is also an
ongoing Dissemination effort to reach physicians, patients, and formulary
benefits managers with the core messages of ALLHAT and the Seventh Report of
the Joint National Committee on the Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7).
|
|
The original ALLHAT protocol may be found at
http://allhat.sph.uth.tmc.edu/Forms/protocol.pdf
|
| Post-Trial
Follow-up of ALLHAT Participants |
|
|
| Active
follow-up of ALLHAT participants ended on March 31, 2002 (February 15, 2000 for
doxazosin participants), for an average follow-up of 4.9 years (3.2 years for
doxazosin). To answer additional scientific questions, a post-trial follow-up
of participants through 2006 is planned to obtain data on post-trial morbidity
and mortality. The extended follow-up will be carried out passively using
national databases available through the National Death Index (NDI), Social
Security Administration (SSA), Centers for Medicare and Medicaid Services
(CMS), Department of Veterans Affairs (DVA), and United States Renal Data
System (USRDS). When completed, endpoint data will be available for between 9
and 10 years of total follow-up.
|
|
The overall research objective of this extended follow-up is to compare
long-term effects of antihypertensive treatment with a thiazide-type diuretic,
a CCB, an ACE-inhibitor, or an a-receptor blocker when each drug is used as
initial treatment with step-up drugs added as needed and, for the lipid
component, to assess long-term effects of pravastatin compared with usual care.
To meet these objectives, we will evaluate whether new differences emerge for
outcomes that were not statistically different, especially CVD and total
mortality, and whether the differences observed during the trial continue.
|
|
The ALLHAT extension protocol was developed by the CTC and the NHLBI Project
Office and approved by the ALLHAT Steering Committee.
|
|
The link to the full extension protocol is
http://allhat.sph.uth.tmc.edu/Forms/ExtensionProtocol.pdf
|
